Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Orionis Biosciences BV is currently engaged in patent prosecution within the Biotechnology & Pharmaceuticals technology area. The company has 5 pending office actions, which are distributed across 4 distinct art units. This distribution across 4 distinct art units indicates that the company's research and development efforts cover several specialized niches within the biological sciences. Because the workload is split among 4 distinct art units, the prosecution strategy must account for the different technical perspectives and examination standards of each group.
The portfolio is being reviewed by 5 distinct examiners, ensuring that each of the 5 pending office actions receives an independent evaluation. WANG, CHANG YU is the busiest examiner, currently responsible for 1 pending office action. Since each of the 5 distinct examiners handles a portion of the pending workload, no single individual has a dominant influence on the overall portfolio. This decentralized arrangement requires the company to maintain a flexible approach to prosecution in Biotechnology & Pharmaceuticals, as they must satisfy the specific requirements of 5 distinct examiners. The presence of 5 pending office actions indicates a focused but multi-faceted approach to securing intellectual property rights.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
| JUEDES, AMY E | 1 | 44.7% | +41.9% |
| HOPKINS, SAMANTHA LAKE | 1 | 60.7% | +61.5% |
| RAMADAN, OMAR | 1 | 25.4% | +56.5% |
| DUFFY, BRADLEY | 1 | 54.4% | +46.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17415248 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | RAMADAN, OMAR | 26d |
| 18574857 | INTERLEUKIN-1 ALPHA CHIMERIC PROTEIN | JUEDES, AMY E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17415248 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | RAMADAN, OMAR | 26d |
| 18668770 | CLEC9A BINDING AGENTS AND USE THEREOF | WANG, CHANG YU | — |
| 18574857 | INTERLEUKIN-1 ALPHA CHIMERIC PROTEIN | JUEDES, AMY E | — |
| 17598570 | CHIMERIC PROTEINS AND CHIMERIC PROTEIN COMPLEXES DIRECTED TO FMS-LIKE TYROSINE KINASE 3 (FLT3) | HOPKINS, SAMANTHA LAKE | — |
| 17042512 | BI-FUNCTIONAL PROTEINS AND CONSTRUCTION THEREOF | DUFFY, BRADLEY | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1641 | 1 |
| 1678 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18668770 | CLEC9A BINDING AGENTS AND USE THEREOF | WANG, CHANG YU | 1675 | §112DP | Non-Final OA | — | Pending | May 20, 2024 |
| 18574857 | INTERLEUKIN-1 ALPHA CHIMERIC PROTEIN | JUEDES, AMY E | — | §102§103§112 | Non-Final OA | — | Pending | Dec 28, 2023 |
| 17598570 | CHIMERIC PROTEINS AND CHIMERIC PROTEIN COMPLEXES DIRECTED TO FMS-LIKE TYROSINE KINASE 3 (FLT3) | HOPKINS, SAMANTHA LAKE | 1641 | §112DP | Non-Final OA | — | Pending | Sep 27, 2021 |
| 17415248 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | RAMADAN, OMAR | 1678 | §103 | Non-Final OA | 26d | Pending | Jun 17, 2021 |
| 17042512 | BI-FUNCTIONAL PROTEINS AND CONSTRUCTION THEREOF | DUFFY, BRADLEY | 1643 | §103 | Final Rejection | — | Pending | Sep 28, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOrionis Biosciences BV has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Chang Yu Wang has the most, with 1 of Orionis Biosciences BV's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
